In diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), USP9X deubiquitinates Mcl-1 and protects it from degrading, while high-level Mcl-1 is associated with malignant B-cell proliferation and poor outcomes in B-cell lymphoma patients [154]. Here, MCL1 is linked to B-cell non-Hodgkin lymphoma.